Severe CNS depression with duloxetine, ciprofloxacin and CYP2D6 deficiency-role and recognition of drug-drug-gene interactions

Eur J Clin Pharmacol. 2022 Apr;78(4):703-705. doi: 10.1007/s00228-022-03278-2. Epub 2022 Jan 17.

Authors

Matthias Hoffmann¹, Stefan Russmann^{2

3

4}, David F Niedrig^{5

6}

Affiliations

¹ Institute of Internal Medicine, Clinic Hirslanden, Zurich, Switzerland.
² Institute of Internal Medicine, Clinic Hirslanden, Zurich, Switzerland. rustefan@ethz.ch.
³ , drugsafety.ch, Küsnacht, Switzerland. rustefan@ethz.ch.
⁴ Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland. rustefan@ethz.ch.
⁵ , drugsafety.ch, Küsnacht, Switzerland.
⁶ Hospital Pharmacy, Clinic Hirslanden, Zurich, Switzerland.

PMID: 35039909
DOI: 10.1007/s00228-022-03278-2

No abstract available

Publication types

Letter

MeSH terms

Ciprofloxacin* / adverse effects
Cytochrome P-450 CYP2D6* / genetics
Depression
Drug Interactions
Duloxetine Hydrochloride / adverse effects
Humans

Substances

Ciprofloxacin
Duloxetine Hydrochloride
Cytochrome P-450 CYP2D6